Business Wire

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-355 in Patients with Solid Tumors Harboring Oncogene Amplification

POTENTIATE (Precision Oncology Trial Evaluating Novel Therapeutic Interrupting Amplifications Tied to ecDNA) is a first-in-human, 3-part, Phase 1/2 study of BBI-355 as a single agent and in ...
Business Wire

Boundless Bio Presents Preclinical Data on the Discovery of its Second ecDNA-Directed Therapeutic Candidate, BBI-825, at the 2023 AACR-NCI-EORTC International Conference on ...

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, a clinical stage, next-generation precision oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to ...
FierceBiotech

Novo's investment arm gains toehold in diagnostics with £400M deal for testing supplier BBI

Even though the demand for COVID-19 testing may have passed its peak, the global need for diagnostics in preventive and routine care continues to grow—and now Novo Holdings wants to become further ...
Nasdaq

Boundless Bio Reports Q1 2025 Financial Results and Progress on BBI-355 Phase 1/2 Trial and Kinesin Program Development

Boundless Bio, a clinical-stage oncology company, announced its financial results for the first quarter of 2025, highlighting its ongoing commitments to developing innovative therapies for patients ...
Bloomberg L.P.

Sinopharm Explores $1 Billion Deal for BBI Life Sciences

China National Pharmaceutical Group Co. is among suitors exploring a potential acquisition of BBI Life Sciences Corp., in a deal that could value the Shanghai-based DNA synthesis products supplier at ...